ClinicalTrials.gg
CompletedNCT00437281Updated Feb 11, 2021Results posted

Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures

A Phase 1/2 interventional study of Placebo and Pregabalin in Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 18 sites in 3 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2021-02-11.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
1 Month to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.

Enrollment
15th of 18
65 · median 244
Started
2007
with 4 others
Phase 1/2
Only one
of the 18
Registered
10th of 18
by date
Lead sponsor
10 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 15th largest by enrollment, is one of 5 that started in 2007, is the only one in phase 1/2, and was the 10th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 1 Month to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing pregabalin in Epilepsies, Partial as a file.
02

Study summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of pregabalin in pediatric patients with partial onset seizures that are incompletely controlled on their current medications.

03

Conditions studied

  • Epilepsies, Partial

Keywords

  • Partial-onset seizures; epilepsy; pediatric; pregabalin; safety; tolerability; pharmacokinetics
04

Who can participate

Ages eligible
1 Month to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Partial onset seizures, incompletely controlled on 1-3 medications
  • At least 1 seizure per 28 days, on average

Exclusion criteria

Exclusion Criteria:

  • Primary generalized seizures
  • Progressive CNS pathology
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Pregabalin

    Drug: Pregabalin

Interventions

  • DrugPlacebo

    Placebo

  • Orally-administered pregabalin

06

What researchers measure

Primary outcomes

  1. Number of Treatment-Emergent Adverse Events (AEs) by Severity: Double-blind Treatment

    Analysis for severity of AEs was performed separately for double-blind and open-label treatment. AE = any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment: Mild = no interference with participant's usual function; Moderate = some interference with participant's usual function; Severe = significant interference with participant's usual function. Treatment-emergent events for double-blind treatment included events between baseline and Day 7 that were absent before treatment or that worsened relative to pretreatment state. Participants may experience more than 1 AE.

    Time frame: Baseline to Day 7

  2. Number of Treatment-Emergent Adverse Events (AEs) by Severity: Open-label Treatment

    Analysis for severity of AEs was performed separately for double-blind and open-label treatment. AE = any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment: Mild = no interference with participant's usual function; Moderate = some interference with participant's usual function; Severe = significant interference with participant's usual function. Treatment-emergent events for open-label treatment included events between Day 8 and 28 days after the open-label dose that were absent before treatment or that worsened relative to pretreatment state. Participants may experience more than 1 AE.

    Time frame: Day 8 up to 28 days after open-label dose of study medication

Secondary outcomes

  1. Number of Participants With Clinically Significant Change in Physical and Neurological Findings

    Full physical examination included examination of the abdomen, breasts, lungs, lymph nodes, mouth, genitourinary, musculoskeletal and neurological systems, skin, extremities, head, heart, ears, eyes, neck, nose, ocular fundi, throat and thyroid gland. The neurological exam was performed by a pediatric neurologist or qualified investigator.

    Time frame: Baseline up to 7 days post-last dose of study medication

  2. 28-Day Seizure Frequency Rate

    Seizure frequency was reported by participant's parent or guardian from randomization to 7 days post-last dose of study medication. 28-day seizure frequency rate = (number of seizures in observation period/number of days in observation period)\*28.

    Time frame: Baseline up to 7 days post-last dose of study medication

  3. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau): Multiple-Dose Analysis

    Area under the curve from time zero to the end of dosing interval (AUCtau), where dosing interval was 12 hours, for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants). Results are normalized to individual participant's Day 8 dose.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose on Day 8

  4. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: Single-Dose Analysis

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants). Results are normalized to individual participant's Day 8 dose.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8

  5. Maximum Observed Plasma Concentration (Cmax): Multiple-Dose Analysis

    Cmax for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants). Results are normalized to individual participant's Day 8 dose.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8

  6. Maximum Observed Plasma Concentration (Cmax): Single-Dose Analysis

    Cmax for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants). Results are normalized to individual participant's Day 8 dose.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8

  7. Time to Reach Maximum Observed Plasma Concentration (Tmax): Multiple-Dose Analysis

    Tmax for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8

  8. Time to Reach Maximum Observed Plasma Concentration (Tmax): Single-Dose Analysis

    Tmax for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8

  9. Plasma Decay Half-Life (t1/2): Multiple-Dose Analysis

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. t1/2 for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8

  10. Plasma Decay Half-Life (t1/2): Single-Dose Analysis

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. t1/2 for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8

  11. Apparent Oral Clearance (CL/F): Multiple-Dose Analysis

    Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8

  12. Apparent Oral Clearance (CL/F): Single-Dose Analysis

    Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).

    Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8

  13. Renal Clearance (CLr): Multiple-Dose Analysis

    Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time. CLr for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).

    Time frame: 0 to 12 hours post-dose, 12 to 24 hours post-dose on Day 8

  14. Renal Clearance (CLr): Single-Dose Analysis

    Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time. CLr for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning was to be reported (single-dose participants).

    Time frame: 0 to 12 hours post-dose, 12 to 24 hours post-dose on Day 8

07

Results

Posted Mar 17, 2014
Limitations and caveats
Results are reported for AUCtau for multiple-dose PK analysis and AUC (0-∞) for single-dose PK analysis, instead of AUC (0-24), as per change in planned analysis.

Participant flow

Participant flow — Overall Study
MilestonePregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Placebo (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Placebo (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Placebo (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)Placebo (Age Cohort: 12 to 16 Years)
Started33334433353323533423
Completed33324333343322433412
Not completed00010100010001100011
Withdrew: Adverse event00010100010001100010
Withdrew: Lost to follow-up00000000000000000001

Outcome measures

SecondaryNumber of Participants With Clinically Significant Change in Physical and Neurological Findings

Full physical examination included examination of the abdomen, breasts, lungs, lymph nodes, mouth, genitourinary, musculoskeletal and neurological systems, skin, extremities, head, heart, ears, eyes, neck, nose, ocular fundi, throat and thyroid gland. The neurological exam was performed by a pediatric neurologist or qualified investigator.

Time frame:
Baseline up to 7 days post-last dose of study medication
Reported as:
Number · participants
Number of Participants With Clinically Significant Change in Physical and Neurological Findings
participantsPregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Placebo (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Placebo (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Placebo (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)Placebo (Age Cohort: 12 to 16 Years)
Number of Participants With Clinically Significant Change in Physical and Neurological Findings00000100010011000100
PrimaryNumber of Treatment-Emergent Adverse Events (AEs) by Severity: Double-blind Treatment

Analysis for severity of AEs was performed separately for double-blind and open-label treatment. AE = any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment: Mild = no interference with participant's usual function; Moderate = some interference with participant's usual function; Severe = significant interference with participant's usual function. Treatment-emergent events for double-blind treatment included events between baseline and Day 7 that were absent before treatment or that worsened relative to pretreatment state. Participants may experience more than 1 AE.

Time frame:
Baseline to Day 7
Reported as:
Number · adverse events
Number of Treatment-Emergent Adverse Events (AEs) by Severity: Double-blind Treatment
adverse eventsPregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Placebo (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Placebo (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Placebo (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)Placebo (Age Cohort: 12 to 16 Years)
Mild0224114551303352021120
Moderate11011200032002011430
Severe00010000000003001000
Secondary28-Day Seizure Frequency Rate

Seizure frequency was reported by participant's parent or guardian from randomization to 7 days post-last dose of study medication. 28-day seizure frequency rate = (number of seizures in observation period/number of days in observation period)\*28.

Time frame:
Baseline up to 7 days post-last dose of study medication

No measurements were reported for this outcome.

SecondaryArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau): Multiple-Dose Analysis

Area under the curve from time zero to the end of dosing interval (AUCtau), where dosing interval was 12 hours, for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants). Results are normalized to individual participant's Day 8 dose.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose on Day 8
Reported as:
Geometric mean · (microgram*hour/milliliter)/(mg/kg)
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau): Multiple-Dose Analysis
(microgram*hour/milliliter)/(mg/kg)Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau): Multiple-Dose Analysis7.614 ± 197.563 ± 267.595 ± 6NA ± NA7.962 ± 29NA ± NANA ± NA8.203 ± 3111.64 ± 299.571 ± 97.59NA ± NA10.20 ± 1313.07 ± 349.642 ± 4414.4
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: Single-Dose Analysis

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants). Results are normalized to individual participant's Day 8 dose.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Reported as:
Geometric mean · (microgram*hour/milliliter)/(mg/kg)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: Single-Dose Analysis
(microgram*hour/milliliter)/(mg/kg)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: Single-Dose Analysis6.708.107.057.028.306.388.769.1610.010.18.0015.913.810.6——
SecondaryMaximum Observed Plasma Concentration (Cmax): Multiple-Dose Analysis

Cmax for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants). Results are normalized to individual participant's Day 8 dose.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Reported as:
Geometric mean · (microgram/milliliter)/(mg/kg)
Maximum Observed Plasma Concentration (Cmax): Multiple-Dose Analysis
(microgram/milliliter)/(mg/kg)Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)
Maximum Observed Plasma Concentration (Cmax): Multiple-Dose Analysis1.468 ± 231.577 ± 111.496 ± 14NA ± NA1.601 ± 13NA ± NANA ± NA1.856 ± 152.350 ± 291.660 ± 130.945NA ± NA1.762 ± 222.538 ± 441.355 ± 591.94
SecondaryMaximum Observed Plasma Concentration (Cmax): Single-Dose Analysis

Cmax for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants). Results are normalized to individual participant's Day 8 dose.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Reported as:
Geometric mean · (microgram/milliliter)/(mg/kg)
Maximum Observed Plasma Concentration (Cmax): Single-Dose Analysis
(microgram/milliliter)/(mg/kg)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years)
Maximum Observed Plasma Concentration (Cmax): Single-Dose Analysis1.511.811.181.521.931.501.701.541.312.291.241.281.811.79——
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax): Multiple-Dose Analysis

Tmax for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax): Multiple-Dose Analysis
hoursPregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)
Time to Reach Maximum Observed Plasma Concentration (Tmax): Multiple-Dose Analysis0.617 (0.500 to 1.00)1.05 (1.00 to 2.08)1.12 (1.02 to 2.00)2.49 (0.967 to 4.02)0.500 (0.500 to 2.00)1.67 (1.17 to 2.17)2.62 (1.17 to 4.07)1.00 (0.967 to 1.17)0.583 (0.583 to 1.00)1.00 (1.00 to 1.00)4.000.790 (0.500 to 1.08)0.500 (0.500 to 4.00)0.583 (0.483 to 1.00)2.09 (1.50 to 8.08)2.15
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax): Single-Dose Analysis

Tmax for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax): Single-Dose Analysis
hoursPlacebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years)
Time to Reach Maximum Observed Plasma Concentration (Tmax): Single-Dose Analysis1.000.9671.131.000.4501.001.001.981.000.5832.004.004.051.00——
SecondaryPlasma Decay Half-Life (t1/2): Multiple-Dose Analysis

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. t1/2 for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2): Multiple-Dose Analysis
hoursPregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)
Plasma Decay Half-Life (t1/2): Multiple-Dose Analysis4.433 ± 0.175593.397 ± 0.586033.263 ± 0.49903NA ± NA3.90NA ± NA3.523 ± 0.251463.520 ± 0.918044.287 ± 0.277374.113 ± 0.25891NA ± NANA ± NA4.960 ± 1.38573.953 ± 0.805325.643 ± 0.889216.61
SecondaryPlasma Decay Half-Life (t1/2): Single-Dose Analysis

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. t1/2 for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2): Single-Dose Analysis
hoursPlacebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years)
Plasma Decay Half-Life (t1/2): Single-Dose Analysis2.643.783.763.223.882.703.833.084.774.023.136.545.803.85——
SecondaryApparent Oral Clearance (CL/F): Multiple-Dose Analysis

Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Reported as:
Geometric mean · milliliter/minute (mL/min)
Apparent Oral Clearance (CL/F): Multiple-Dose Analysis
milliliter/minute (mL/min)Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)
Apparent Oral Clearance (CL/F): Multiple-Dose Analysis19.00 ± 1017.70 ± 4718.54 ± 49NA ± NA34.18 ± 61NA ± NANA ± NA30.49 ± 958.23 ± 4249.49 ± 1963.7NA ± NA90.56 ± 2678.38 ± 1285.87 ± 1773.1
SecondaryApparent Oral Clearance (CL/F): Single-Dose Analysis

Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).

Time frame:
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Reported as:
Geometric mean · mL/min
Apparent Oral Clearance (CL/F): Single-Dose Analysis
mL/minPlacebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years)
Apparent Oral Clearance (CL/F): Single-Dose Analysis31.524.720.128.032.360.138.845.558.245.864.854.399.690.0——
SecondaryRenal Clearance (CLr): Multiple-Dose Analysis

Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time. CLr for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).

Time frame:
0 to 12 hours post-dose, 12 to 24 hours post-dose on Day 8
Reported as:
Geometric mean · mL/min
Renal Clearance (CLr): Multiple-Dose Analysis
mL/minPregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)
Renal Clearance (CLr): Multiple-Dose Analysis—21.0——8.77—48.411.5—24.75 ± 8855.936.9—NA ± NA69.16 ± 39—
SecondaryRenal Clearance (CLr): Single-Dose Analysis

Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time. CLr for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning was to be reported (single-dose participants).

Time frame:
0 to 12 hours post-dose, 12 to 24 hours post-dose on Day 8
Reported as:
Geometric mean · mL/min
Renal Clearance (CLr): Single-Dose Analysis
mL/minPlacebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years)Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years)Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years)
Renal Clearance (CLr): Single-Dose Analysis———————————42.6—73.8——
PrimaryNumber of Treatment-Emergent Adverse Events (AEs) by Severity: Open-label Treatment

Analysis for severity of AEs was performed separately for double-blind and open-label treatment. AE = any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment: Mild = no interference with participant's usual function; Moderate = some interference with participant's usual function; Severe = significant interference with participant's usual function. Treatment-emergent events for open-label treatment included events between Day 8 and 28 days after the open-label dose that were absent before treatment or that worsened relative to pretreatment state. Participants may experience more than 1 AE.

Time frame:
Day 8 up to 28 days after open-label dose of study medication
Reported as:
Number · adverse events
Number of Treatment-Emergent Adverse Events (AEs) by Severity: Open-label Treatment
adverse eventsPregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Placebo (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Placebo (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Placebo (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)Placebo (Age Cohort: 12 to 16 Years)
Mild00012000010010000000
Moderate00001000110000101000
Severe00000000000000101000

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)—0/3 (0%)1/3 (33.3%)
Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)—0/3 (0%)2/3 (66.7%)
Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)—0/3 (0%)1/3 (33.3%)
Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)—0/3 (0%)3/3 (100%)
Placebo (Age Cohort: 1 to 23 Months)—0/4 (0%)2/4 (50%)
Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)—0/4 (0%)2/4 (50%)
Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)—0/3 (0%)1/3 (33.3%)
Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)—0/3 (0%)2/3 (66.7%)
Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)—0/3 (0%)2/3 (66.7%)
Placebo (Age Cohort: 2 to 6 Years)—0/5 (0%)4/5 (80%)
Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)—0/3 (0%)2/3 (66.7%)
Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)—0/3 (0%)3/3 (100%)
Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)—0/2 (0%)2/2 (100%)
Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)—1/3 (33.3%)2/3 (66.7%)
Placebo (Age Cohort: 7 to 11 Years)—1/5 (20%)2/5 (40%)
Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)—0/3 (0%)1/3 (33.3%)
Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)—0/3 (0%)1/3 (33.3%)
Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)—0/4 (0%)4/4 (100%)
Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)—0/2 (0%)2/2 (100%)
Placebo (Age Cohort: 12 to 16 Years)—0/3 (0%)0/3 (0%)
Most frequent serious events
Most frequent serious events
EventPregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Placebo (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Placebo (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Placebo (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)Placebo (Age Cohort: 12 to 16 Years)
AtaxiaNervous system disorders0/30/30/30/30/40/40/30/30/30/50/30/30/21/30/50/30/30/40/20/3
SomnolenceNervous system disorders0/30/30/30/30/40/40/30/30/30/50/30/30/21/30/50/30/30/40/20/3
ConvulsionNervous system disorders0/30/30/30/30/40/40/30/30/30/50/30/30/20/31/50/30/30/40/20/3
Most frequent other events
Showing 10 of 51
Most frequent other events
EventPregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Placebo (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Placebo (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Placebo (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)Placebo (Age Cohort: 12 to 16 Years)
DizzinessNervous system disorders0/30/30/30/30/40/40/31/30/30/50/30/30/22/30/50/30/32/41/20/3
SomnolenceNervous system disorders0/32/30/32/32/41/41/30/30/30/52/31/30/21/30/51/30/30/41/20/3
NauseaGastrointestinal disorders0/30/30/30/30/40/40/30/30/30/50/30/30/20/30/50/30/30/41/20/3
VomitingGastrointestinal disorders0/30/31/30/30/40/40/31/30/31/50/30/30/20/30/50/30/31/41/20/3
Upper respiratory tract infectionInfections and infestations0/30/30/30/30/40/40/30/30/31/50/30/31/20/30/50/30/30/40/20/3
Muscular weaknessMusculoskeletal and connective tissue disorders0/30/30/30/30/40/40/30/30/30/50/30/31/20/30/50/30/30/40/20/3
Balance disorderNervous system disorders0/30/30/30/30/40/40/30/30/30/50/30/30/20/30/50/30/30/41/20/3
LethargyNervous system disorders0/30/30/30/30/41/40/30/30/31/50/30/31/20/31/50/30/30/40/20/3
Psychomotor hyperactivityNervous system disorders0/30/30/30/30/40/40/30/30/30/50/30/31/20/30/50/30/30/40/20/3
DiarrhoeaGastrointestinal disorders0/30/30/30/30/40/40/30/30/32/50/30/30/20/30/50/30/30/40/20/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Placebo (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Placebo (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Placebo (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)Placebo (Age Cohort: 12 to 16 Years)Total
Mean1.2 ± 0.71.4 ± 0.50.7 ± 0.50.6 ± 0.11.6 ± 0.34.0 ± 0.82.9 ± 0.14.0 ± 1.73.9 ± 1.83.7 ± 1.09.3 ± 1.29.7 ± 2.310.0 ± 0.09.0 ± 1.09.2 ± 1.515.7 ± 0.613.7 ± 2.114.0 ± 1.815.5 ± 0.713.0 ± 1.76.9 ± 5.2
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months)Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months)Placebo (Age Cohort: 1 to 23 Months)Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years)Placebo (Age Cohort: 2 to 6 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years)Placebo (Age Cohort: 7 to 11 Years)Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years)Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years)Placebo (Age Cohort: 12 to 16 Years)Total
Female1212242113210042100332
Male2121201222122311242033
08

Study locations

18 sites
  • Pfizer Investigational Site
    Mobile, Alabama 36604, United States
  • Pfizer Investigational Site
    Mobile, Alabama 36693, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85016, United States
  • Pfizer Investigational Site
    Jonesboro, Arkansas 72401, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    San Francisco, California 94143, United States
  • Pfizer Investigational Site
    Gulf Breeze, Florida 32561, United States
  • Pfizer Investigational Site
    Pensacola, Florida 32504, United States
  • Pfizer Investigational Site
    Tampa, Florida 33603, United States
  • Pfizer Investigational Site
    Tampa, Florida 33609, United States
  • Pfizer Investigational Site
    Springfield, Missouri 65804, United States
  • Pfizer Investigational Site
    Buffalo, New York 14222, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27710, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78258, United States
  • Pfizer Investigational Site
    Seoul, 120-752, Korea, Republic of
  • Pfizer Investigational Site
    Mexico, DF 06720, Mexico
  • Pfizer Investigational Site
    Guadalajara, Jalisco 44280, Mexico
09

References and documents

Publications

  • Mann D, Liu J, Chew ML, Bockbrader H, Alvey CW, Zegarac E, Pellock J, Pitman VW. Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: a phase 1, randomized controlled study. Epilepsia. 2014 Dec;55(12):1934-43. doi: 10.1111/epi.12830. Epub 2014 Nov 6. PubMed 25377429 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2007
First posted
Feb 19, 2007
Start
Apr 2007
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Mar 17, 2014
Last update
Feb 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00437281
Responsible party
Sponsor
First posted
Feb 19, 2007
Start date
Apr 2007
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Mar 17, 2014
Last update
Feb 11, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion